Eagle Pharmaceuticals Inc Cash Flow Conversion Efficiency
Eagle Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Eagle Pharmaceuticals Inc (EGRX) has a cash flow conversion efficiency ratio of 0.000x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-126.00K) by net assets ($252.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Eagle Pharmaceuticals Inc (2012–2022)
Cash flow conversion efficiency of Eagle Pharmaceuticals Inc from 2012 to 2022. This chart illustrates how Eagle Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View EGRX share price today for real-time trading data and today's change.
Eagle Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Eagle Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Eagle Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eagle Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see market value of Eagle Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Linkage Global Inc
NASDAQ:UZX
|
N/A |
|
Marvel Discovery Corp
V:MARV
|
0.000x |
|
Kedaung Indah Can Tbk
JK:KICI
|
-0.009x |
|
AEST.MED.INT.HLD.SP.ADR/3
F:3FMA
|
N/A |
|
Thunderstruck Resources Ltd
V:AWE
|
-0.004x |
|
Golden Sky Minerals Corp
V:AUEN
|
0.777x |
|
New Zealand Coastal Seafoods Ltd
AU:NZS
|
-0.786x |
|
Property Franchise Group PLC
LSE:TPFG
|
0.089x |
Annual Cash Flow Conversion Efficiency for Eagle Pharmaceuticals Inc (2012–2022)
The table below shows the annual cash flow conversion efficiency of Eagle Pharmaceuticals Inc from 2012 to 2022. Review Eagle Pharmaceuticals Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $233.56 Million | $30.80 Million | 0.132x | -17.55% |
| 2021-12-31 | $176.45 Million | $28.22 Million | 0.160x | -39.90% |
| 2020-12-31 | $186.01 Million | $49.50 Million | 0.266x | -14.84% |
| 2019-12-31 | $179.17 Million | $55.99 Million | 0.312x | -4.11% |
| 2018-12-31 | $160.76 Million | $52.38 Million | 0.326x | -0.93% |
| 2017-12-31 | $179.14 Million | $58.92 Million | 0.329x | -6.52% |
| 2016-12-31 | $151.23 Million | $53.21 Million | 0.352x | +427.08% |
| 2015-12-31 | $90.34 Million | $-9.72 Million | -0.108x | +74.28% |
| 2014-12-31 | $33.10 Million | $-13.84 Million | -0.418x | +85.39% |
| 2013-12-31 | $2.05 Million | $-5.88 Million | -2.863x | -322.75% |
| 2012-12-31 | $-12.10 Million | $-15.55 Million | 1.285x | -- |
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non… Read more